News | January 30, 2026
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
Subscribe To Our Newsletter & Stay Updated
